Literature DB >> 35522321

Clinicopathological features of gastric cancer after pancreaticoduodenectomy: reporting of three institutional cases and review of the global literature.

Tatsuaki Sumiyoshi1, Kenichiro Uemura2, Naru Kondo1, Kenjiro Okada1, Shingo Seo1, Hiroyuki Otsuka1, Shinya Takahashi1.   

Abstract

PURPOSE: Gastric cancer after pancreaticoduodenectomy was firstly reported in 1995, and the number of reports about this topic has increased in the past years. This review aimed to elucidate the clinicopathological features of this disease.
METHODS: Data for 32 cases were obtained using literature search, and three cases in our institution were added.
RESULTS: Twenty cases were reported from Japan, and fifteen cases were from the Western countries (Germany: 1 case, France: 2 cases, USA: 12 cases). In Japanese and the Western cases, the most dominant indication for pancreaticoduodenectomy was distal bile duct cancer and pancreatic ductal adenocarcinoma, respectively. The most frequently applied procedure of pancreaticoduodenectomy was pylorus-preserving pancreatoduodenectomy with pancreaticogastrostomy and pancreaticoduodenectomy with pancreaticojejunostomy, respectively. The median length of time interval from pancreaticoduodenectomy to GC detection tended to be shorter in the Japanese cases (61.5 months vs. 115 months). Of all cases, thirteen (37.1%) patients with gastric cancer showed no abdominal symptoms, and eight were diagnosed at regular gastroscopy. Surgical gastrectomy was performed in 30 patients, and among them, concomitant pancreatectomy was performed in six patients. Four patients received reanastomosis of remnant pancreas using pancreaticojejunostomy. Twenty-two (73.3%) patients had undifferentiated carcinomas, and stage 1, 2, 3, and 4 cancer was identified in 14, six, six, and four patients, respectively. All eight patients who had received routine gastroscopy were T1N0M0 stage 1.
CONCLUSION: Gastric cancers after pancreaticoduodenectomy including newly reported Japanese cases and our institutional cases were reviewed to make Japanese studies available to a broader scientific audience. Further investigation is necessary to elucidate the most important carcinogens among the various potential local and systemic factors.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Gastric cancer; PDAC; PPPD; Pancreaticoduodenectomy; Pancreaticogastrostomy; Pancreaticojejunostomy; Stomach cancer

Mesh:

Year:  2022        PMID: 35522321     DOI: 10.1007/s00423-022-02524-6

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   2.895


  25 in total

1.  Two thousand consecutive pancreaticoduodenectomies.

Authors:  John L Cameron; Jin He
Journal:  J Am Coll Surg       Date:  2015-01-06       Impact factor: 6.113

2.  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

Authors:  John P Neoptolemos; Daniel H Palmer; Paula Ghaneh; Eftychia E Psarelli; Juan W Valle; Christopher M Halloran; Olusola Faluyi; Derek A O'Reilly; David Cunningham; Jonathan Wadsley; Suzanne Darby; Tim Meyer; Roopinder Gillmore; Alan Anthoney; Pehr Lind; Bengt Glimelius; Stephen Falk; Jakob R Izbicki; Gary William Middleton; Sebastian Cummins; Paul J Ross; Harpreet Wasan; Alec McDonald; Tom Crosby; Yuk Ting Ma; Kinnari Patel; David Sherriff; Rubin Soomal; David Borg; Sharmila Sothi; Pascal Hammel; Thilo Hackert; Richard Jackson; Markus W Büchler
Journal:  Lancet       Date:  2017-01-25       Impact factor: 79.321

3.  A collision tumor composed of adenocarcinoma and malignant lymphoma in the remnant stomach after pancreatoduodenectomy: report of a case.

Authors:  T Manabe; K Nishihara; Y Kurokawa; Y Hattanda; S Toyoshima; S Takeda; R Abe
Journal:  Surg Today       Date:  2001       Impact factor: 2.549

Review 4.  Gastric cancer arising from the remnant stomach after distal gastrectomy: a review.

Authors:  Shinsuke Takeno; Tatsuya Hashimoto; Kenji Maki; Ryosuke Shibata; Hironari Shiwaku; Ippei Yamana; Risako Yamashita; Yuichi Yamashita
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

5.  Meta-analysis of the risk of gastric stump cancer: detection of high risk patient subsets for stomach cancer after remote partial gastrectomy for benign conditions.

Authors:  A C Tersmette; G J Offerhaus; K W Tersmette; F M Giardiello; G W Moore; G N Tytgat; J P Vandenbroucke
Journal:  Cancer Res       Date:  1990-10-15       Impact factor: 12.701

6.  Gastric cancer following pancreaticoduodenectomy: Experience from a high-volume center and review of existing literature.

Authors:  Michael Johannes Pflüger; Matthäus Felsenstein; Ryan Schmocker; Laura DeLong Wood; Ralph Hruban; Kohei Fujikura; Noah Rozich; Floortje van Oosten; Matthew Weiss; William Burns; Jun Yu; John Cameron; Johann Pratschke; Christopher Lee Wolfgang; Jin He; Richard Andrew Burkhart
Journal:  Surg Open Sci       Date:  2020-08-16

7.  Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).

Authors:  Fuyuhiko Motoi; Tomoo Kosuge; Hideki Ueno; Hiroki Yamaue; Sohei Satoi; Masayuki Sho; Goro Honda; Ippei Matsumoto; Keita Wada; Junji Furuse; Yutaka Matsuyama; Michiaki Unno
Journal:  Jpn J Clin Oncol       Date:  2019-02-01       Impact factor: 3.019

8.  Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).

Authors:  Katsuhiko Uesaka; Narikazu Boku; Akira Fukutomi; Yukiyasu Okamura; Masaru Konishi; Ippei Matsumoto; Yuji Kaneoka; Yasuhiro Shimizu; Shoji Nakamori; Hirohiko Sakamoto; Soichiro Morinaga; Osamu Kainuma; Koji Imai; Naohiro Sata; Shoichi Hishinuma; Hitoshi Ojima; Ryuzo Yamaguchi; Satoshi Hirano; Takeshi Sudo; Yasuo Ohashi
Journal:  Lancet       Date:  2016-06-02       Impact factor: 79.321

9.  Gastric cancer in the remnant stomach after pancreaticoduodenectomy: A case series.

Authors:  Keita Sonoda; Rashmi T Samdani; Naruhiko Ikoma; Dilsa Mizrak Kaya; Mariela Blum-Murphy; Jaffer A Ajani; Brian D Badgwell; Matthew H Katz; Asif Rashid; Jeannelyn S Estrella
Journal:  J Surg Oncol       Date:  2019-09-09       Impact factor: 3.454

10.  Stomach cancer after partial gastrectomy for benign ulcer disease.

Authors:  G Lundegårdh; H O Adami; C Helmick; M Zack; O Meirik
Journal:  N Engl J Med       Date:  1988-07-28       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.